{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:22:10Z","timestamp":1793974930588,"version":"4.8.0"},"reference-count":21,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.2967\/jnumed.123.265986","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T17:20:43Z","timestamp":1697736043000},"page":"79-84","source":"Crossref","is-referenced-by-count":74,"title":["Long-Term Nephrotoxicity of<sup>177<\/sup>Lu-PSMA Radioligand Therapy"],"prefix":"10.2967","volume":"65","author":[{"given":"Lisa","family":"Steinhelfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Lunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisena","family":"Cala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Pfob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmaderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brosch-Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin H.","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"2024011701100693000_65.1.79.1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2024011701100693000_65.1.79.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024011701100693000_65.1.79.3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR."},{"key":"2024011701100693000_65.1.79.4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2022.05.025","article-title":"Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy-like picture","volume":"83","author":"Sch\u00e4fer","year":"2023","journal-title":"Eur Urol."},{"key":"2024011701100693000_65.1.79.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101295"},{"key":"2024011701100693000_65.1.79.6","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2024011701100693000_65.1.79.7","doi-asserted-by":"publisher","DOI":"10.1667\/RR3105"},{"key":"2024011701100693000_65.1.79.8","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024011701100693000_65.1.79.9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2024011701100693000_65.1.79.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2024011701100693000_65.1.79.11","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med."},{"key":"2024011701100693000_65.1.79.12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"2024011701100693000_65.1.79.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030"},{"key":"2024011701100693000_65.1.79.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89442-7"},{"key":"2024011701100693000_65.1.79.15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","article-title":"The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024011701100693000_65.1.79.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2024011701100693000_65.1.79.17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int."},{"key":"2024011701100693000_65.1.79.18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.euf.2020.09.021","article-title":"Clinical trial protocol for LuTectomy: a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to prostatectomy","volume":"7","author":"Dhiantravan","year":"2021","journal-title":"Eur Urol Focus."},{"key":"2024011701100693000_65.1.79.19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","author":"Sundl\u00f6v","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024011701100693000_65.1.79.20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/02841866409134143","article-title":"Radiation nephritis","volume":"2","author":"Luxton","year":"1964","journal-title":"Acta Radiol Ther Phys Biol."},{"key":"2024011701100693000_65.1.79.21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-021-01764-y","article-title":"Radiation-induced kidney toxicity: molecular and cellular pathogenesis","volume":"16","author":"Klaus","year":"2021","journal-title":"Radiat Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T09:11:39Z","timestamp":1705482699000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,2]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.2967\/jnumed.123.265986"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265986","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}